Presentations and Publications

WCD 2023 Primary Poster_19June2023

Presented at the World Congress of Dermatology, July 3-8, 2023

WCD 2023 EASI and Safety Poster_19June2023

Presented at the World Congress of Dermatology, July 3-8, 2023

WCD 2023 Investigator Reported Outcomes Poster_19June2023

Presented at the World Congress of Dermatology, July 3-8, 2023

WCD 2023 Patient Reported Outcomes_19June2023

Presented at the World Congress of Dermatology, July 3-8, 2023

CBP-201 Efficacy by IGA severity_RAD abstract_27March2023

Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, April 30, 2023

Potentially Greater Efficacy with CBP-201 for Adults with Severe versus Moderate Atopic Dermatitis at Baseline: Subgroup Analyses from the WW001 Phase 2 Randomized Trial

2023 RAD Poster – CBP-201 Severity – 18Apr2023

Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, April 30, 2023

Potentially Greater Efficacy with CBP-201 for Adults with Severe versus Moderate Atopic Dermatitis at Baseline: Subgroup Analyses from the WW001 Phase 2 Randomized Trial

CBP-201 CN002 Pivotal_AAD 2023

Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023

CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)

AAD2023 Late Breaker 11Mar2023

Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023

CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)

CBP-201 BodyRegion_AAD 2023 Abstract

Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023

Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

EASI body region_AAD 2023 Presentation_17Mar2023

Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023

Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

CBP-201 investigator rated over time EADV 2022 Abstract

Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

Investigator Rated EADV 2022 Poster

Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

CBP-201 PRO over time EADV 2022 Abstract

Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

PRO-EADV 2022 Poster

Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022